Icotyde is the brand name for icotrokinra first-in-class oral peptide drug.
Medical Use: to treat moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older.
Mechanism of Action: It functions as a selective interleukin-23 (IL-23) receptor antagonist.
By blocking these receptors, it inhibits the inflammatory signaling that causes skin plaques.
Unlike many other IL-23 blockers which are injectables, Icotyde is a daily oral pill, providing a more convenient option for patients.
In Phase 3 trials, it demonstrated superiority over current oral treatments like Sotyktu (deucravacitinib).
A once daily pill which is demonstrated a favorable safety profile with about 70% of patients achieving clear, or almost clear skin after four months in head to head trials versus an active competitor.